BN 80933 inhibits F2-isoprostane elevation in focal cerebral ischaemia and hypoxic neuronal cultures

NeuroReport

Volumn 11, Issue 6, 2000, Pages 1357-1360

  Marin, Jean Grégoire ^a   Cornet, Sylvie ^a   Spinnewyn, Brigitte ^a   Demerlé Pallardy, Caroline ^a   Auguet, Michel ^a   Chabrier, Pierre Etienne ^a  

^a Institut Henri Beaufour   (France)

Author keywords

8 Epi prostaglandin F2 ; BN 80933; Cerebral ischaemia; Cortical cells; F2 Isoprostanes; Middle cerebral artery occlusion; Neuroprotection; Oxidative stress

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ISOPROSTANE; N [4 [4 [(3,4 DIHYDRO 6 HYDROXY 2,5,7,8 TETRAMETHYL 2H 1 BENZOPYRAN 2 YL)CARBONYL] 1 PIPERAZINYL]PHENYL] 2 THIOPHENECARBOXIMIDAMIDE; N [4 [4 [(3,4 DIHYDRO 6 HYDROXY 2,5,7,8 TETRAMETHYL 2H 1BENZOPYRAN 2 YL) CARBONYL] PIPERAZINYL] PHENYL] 2 THIOPHENECARBOXIMIDAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN HYPOXIA; BRAIN ISCHEMIA; DRUG EFFECT; DRUG INHIBITION; ENZYME INHIBITION; GLIA CELL; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REOXYGENATION;

EID: 0034720188     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200004270-00041     Document Type: Article

References (24)

1. 1. van Kooten F, Ciabattoni G, Patrono C et al. Stroke 28, 1557-1563 (1997).
2. 2. Hoffman SW, Roof RL and Stein DG. J Neurosci Methods 68, 133-136 (1996).
3. 3. Roof RL, Hoffman SW and Stein DG. Mol Chem Neuropathol 31, 1-11 (1997).
4. 4. Pratico D, My LV, Trojanowski JQ et al. FASEB J 12, 1777-1783 (1998).
5. 5. Montine TJ, Markesbery WR, Morrow JD et al. Ann Neurol 44, 410-413 (1998).
6. 6. Montine TJ, Beal MF, Robertson D et al. Neurology 52, 1104-1105 (1999).
7. 7. Demerlé-Pallardy C, Roubert V, Marin JG et al. J Neurochem (in press).
8. 8. Chabrier PE, Auguet M, Spinnewyn B et al. Proc Natl Acad Sci USA 96, 10824-10829 (1999).
9. 9. Demerlé-Pallardy C, Lonchampt MO, Chabrier PE et al. Biochem Biophys Res Commun 181, 456-464 (1991).
10. 10. Koh JY and Choi DW. J Neurosci Methods 20, 83-90 (1987).
11. 11. Watson BD. Cell Mol Neurobiol 18, 581-598 (1998).
12. 12. Ikeda J, Ma L, Morita I et al. Acta Neurochir Suppl (Wien) 60, 94-97 (1994).
13. 13. Daval JL, Ghersi-Egea JF, Oillet J et al. J Cerebr Blood Flow Metab 15, 71-77 (1995).
14. 14. Fuson KS, Mark RJ, Panetta JA et al. J Neurochem 72, 1154-1160 (1999).
15. 15. Mark RJ, Fuson KS and May PC. J Neurochem 72, 1146-1153 (1999).
16. 16. Copin JC, Li Y, Reola L et al. Brain Res 784, 25-36 (1998).
17. 17. Braughler JM and Hall ED. Free Radic Biol Med 6, 289-301 (1989).
18. 18. Kuroda S and Siesjo BK. Clin Neurosci 4, 199-212 (1997).
19. 19. Hall ED, Andrus PK, Smith SL et al. J Pharmacol Exp Ther 281, 895-904 (1997).
20. 20. Schmid-Elsaesser R, Zausinger S, Hungerhuber E et al. Stroke 28, 2018-2024 (1997).
21. 21. Yu MJ, McCowan JR, Smalstig EB et al. Stroke 23, 1287-1291 (1992).
22. 22. Morrow JD, Hill KE, Burk RF et al. Proc Natl Acad Sci USA 87, 9383-9387 (1990).
23. 23. Sametz W, Grobuschek T, Hammer-Kogler S et al. Eur J Pharmacol 378, 47-55 (1999).
24. 24. Dettmers C, Young A, Rommel T et al. Acta Neurochir (Wien) 125, 150-155 (1993).